Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 756
- Registration Number
- NCT06726265
- Locations
- 🇧🇪
Algemeen Ziekenhuis Maria Middelares, Gent, Belgium
🇧🇪Clinique et Maternité Sainte-Elisabeth, Namur, Belgium
🇧🇬Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich, Bulgaria
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorAdvanced and/or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 159
- Registration Number
- NCT06724042
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 112
- Registration Number
- NCT06718205
- Locations
- 🇨🇳
Feng Wang, Zhengzhou, Henan, China
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dai, Guanghai
- Target Recruit Count
- 35
- Registration Number
- NCT06708858
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Advanced and Metastatic NSCLC
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 430
- Registration Number
- NCT06704620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
- Conditions
- Oropharynx CancerLarynx CancerHypopharynx CancerPrimary Head and Neck Tumor
- Interventions
- Radiation: Standard radiotherapyRadiation: Tailored radiotherapy
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 460
- Registration Number
- NCT06706401
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
The Minimalist Trial-2
- Conditions
- HPV-Related Oropharynx Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 142
- Registration Number
- NCT06702033
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Combination Product: ASP-1929 Photoimmunotherapy
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung City, Taiwan
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
- Conditions
- Head and Neck Squamous Cell CarcinomaNeoadjuvant TherapyPD-L1Anlotinib
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT06699498
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 60
- Registration Number
- NCT06696742
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.